Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
Lebanon500 participantsStarted 2019-02-01
Plain-language summary
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system. The roles of immune checkpoints, inflammatory and angiogenesis factors, as well as circulating immune cells will be elucidated. Additionally, our investigation extends to the exploration of long non-coding RNAs (LncRNAs) and genes associated with the coagulation vascular system. Initially, these aspects will be evaluated in the context of colorectal cancer, with the intention to expand our research to other solid tumors.
The identification of these biomarkers and genetic factors holds the potential to revolutionize therapeutic approaches for patients with cancer-associated thromboembolism, shedding light on their chemotherapy resistance. The effectiveness of combining immunotherapy with targeted inhibitors like Palbociclib and anticoagulants such as Rivaroxaban, among other potential interventions, will be assessed.
This study aims to make significant contributions to the understanding of these critical aspects, ultimately leading to the development of more effective treatment strategies for cancer patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Individuals of white ethnicity.
* Age between \> 18
* Both males and females.
* Diagnosis of selected cancer type (e.g., colorectal cancer).
* Cancer stage 0/I/II without metastasis or lymph node dissemination at the time of enrollment.
* No previous cancer therapy (radiotherapy, chemotherapy, or immunotherapy) received before study enrollment.
* Unrelated patients.
Exclusion Criteria:
* Cancer stage III/IV.
* History of hematological cancer types or previous cancers, recurrent or relapse.
* Diagnosis of inflammatory bowel diseases.
* Pre-existing cardiovascular diseases or coronary artery diseases.
* Confirmed treated or untreated autoimmune diseases.
* Metabolic disorders, diabetes, or hypertension.
* Neurological diseases.
* Evidence of cardiac, renal, bone, or cerebral damage.
* Presence of more than one type of malignancies.
* Active infections or myositis.
* Familial polyposis.
* Alcohol or smoking habits.
* Colon-affecting food allergies.
* Body mass index (BMI) \>30.
* Significant weight loss within the last 2 years.
* History of abdominal surgeries.
* Pregnancy.
* Related patients.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Venous Thromboembolism (VTE) Events including: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and other Thromboembolic Events (Vein Thrombosis, Portal Vein Thrombosis, Superior Mesenteric Vein Thrombosis, and Renal Vein Thrombosis)
Timeframe: up to 60 months
2
Assessment of Cancer Progression
Timeframe: up to 60 months
3
Identification of Potential Biomarkers
Timeframe: Once at the moment of the patient's enrollment in the study